Status and phase
Conditions
Treatments
About
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients must meet all of the following criteria before entering the group:
Exclusion criteria
Patients cannot participate in this clinical study if they meet any of the following conditions:
Known allergy to the study drug or any of its ingredients; has been treated with sunitinib malate, or allergy to sunitinib malate;
BCR / ABL positive leukemia (chronic myeloid leukemia);
The subjects had central nervous system leukemia;
The subjects had secondary AML after chemotherapy for other tumors (except MDS);
At the same time, patients with other malignant tumors (except for those with cured stage IB or lower grade cervical cancer, non-invasive basal cell or squamous cell skin cancer, malignant melanoma with complete remission (CR) > 10 years, and other malignant tumors with complete remission (CR) > 5 years);
Treatment before the trial:
The toxic and side effects caused by previous treatment did not recover to CTCAE ≤ 1, except for hair loss and other tolerable events judged by the researchers;
Combined diseases:
For female subjects: currently in pregnancy or lactation;
Any previous or current disease, treatment, or laboratory abnormality that may interfere with the results of the study, affect the subject's participation in the whole process of the study, or the subject is not suitable for the study in the opinion of the investigator.
Primary purpose
Allocation
Interventional model
Masking
60 participants in 7 patient groups
Loading...
Central trial contact
Jianxiang Wang, MD; wei Wang, master
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal